Clinical Trials Browser

Phase 2 × Colonic Neoplasms × durvalumab × Clear all

NCT03428126 2023-06-15

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Phase 2 Completed

29 enrolled 9 charts

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms